← All Omeros CORP filings

Omeros CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
OMER
Omeros CORP
10-K/A: Omeros Corporation Files Amendment to 10-K to Include Omitted Information
Omeros Corporation files an amendment to its 2024 annual report to include information previously omitted regarding directors, executive compensation, security ownership, related transactions, and accounting fees.
NASDAQ
OMER
Omeros CORP
10-K: Omeros Corporation Faces Going Concern Doubt Despite Narsoplimab BLA Resubmission
Omeros Corporation's 10-K filing reveals substantial doubt about its ability to continue as a going concern, even as it resubmits its BLA for narsoplimab in TA-TMA and advances other clinical programs.
NASDAQ
OMER
Omeros CORP
10-K: Omeros Corporation Enters Licensing and Royalty Agreements, Expands Pipeline
Omeros Corporation has entered into a license agreement with Asubio Pharma, amended a license agreement with Daiichi Sankyo, and a royalty agreement with DRI Healthcare Acquisitions LP, expanding its therapeutic pipeline and securing funding.